moxifloxacin has been researched along with Recrudescence in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (33.33) | 29.6817 |
| 2010's | 19 (63.33) | 24.3611 |
| 2020's | 1 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, J; Fan, L; He, F; Hu, K; Lei, M; Luo, Q; Qin, S; Shao, X; Yang, L; Yu, N | 1 |
| Chen, H; Chen, S; Wang, F; Wu, M; Xu, J; Xu, P; Zhu, X | 1 |
| Borgman, CJ | 1 |
| Coates, AR; Davies, GR; Gillespie, SH; Hu, Y; Liu, Y; Pertinez, H | 1 |
| Ahmad, N; Ahuja, SD; Akkerman, OW; Alffenaar, JC; Anderson, LF; Baghaei, P; Bang, D; Barry, PM; Bastos, ML; Behera, D; Benedetti, A; Bisson, GP; Boeree, MJ; Bonnet, M; Brode, SK; Brust, JCM; Cai, Y; Caumes, E; Cegielski, JP; Centis, R; Chan, ED; Chan, PC; Chang, KC; Charles, M; Cirule, A; D'Ambrosio, L; Dalcolmo, MP; de Vries, G; Dheda, K; Esmail, A; Flood, J; Fox, GJ; Fréchet-Jachym, M; Fregona, G; Gayoso, R; Gegia, M; Gler, MT; Gu, S; Guglielmetti, L; Holtz, TH; Hughes, J; Isaakidis, P; Jarlsberg, L; Kempker, RR; Keshavjee, S; Khan, FA; Kipiani, M; Koenig, SP; Koh, WJ; Kritski, A; Kuksa, L; Kvasnovsky, CL; Kwak, N; Lan, Z; Lange, C; Laniado-Laborín, R; Lee, M; Leimane, V; Leung, CC; Leung, EC; Li, PZ; Lowenthal, P; Maciel, EL; Marks, SM; Mase, S; Mbuagbaw, L; Menzies, D; Migliori, GB; Milanov, V; Miller, AC; Mitnick, CD; Modongo, C; Mohr, E; Monedero, I; Nahid, P; Ndjeka, N; O'Donnell, MR; Padayatchi, N; Palmero, D; Pape, JW; Podewils, LJ; Reynolds, I; Riekstina, V; Robert, J; Rodriguez, M; Schnippel, K; Seaworth, B; Seung, KJ; Shim, TS; Singla, R; Smith, SE; Sotgiu, G; Sukhbaatar, G; Tabarsi, P; Tiberi, S; Trajman, A; Trieu, L; Udwadia, ZF; van der Werf, TS; Veziris, N; Viiklepp, P; Vilbrun, SC; Walsh, K; Westenhouse, J; Yew, WW; Yim, JJ; Zetola, NM; Zignol, M | 1 |
| Chigutsa, E; Deshpande, D; Gumbo, T; Magombedze, G; McIlleron, H; Pasipanodya, JG; Srivastava, S; Visser, ME | 1 |
| Jiang, RH; Li, L; Xu, HB | 1 |
| Aubry, A; Brossier, F; Chauffour, A; Fillion, A; Jarlier, V; Veziris, N | 1 |
| Balasubramanian, R; Banurekha, VV; Baskaran, D; Chandrasekar, C; Charles, N; Ganapathy, S; Gangadevi, NP; Iliayas, AS; Jagannath, K; Jawahar, MS; Kumar, MM; Kumar, SR; Kumar, V; Mohan, V; Narayanan, PR; Paramasivan, CN; Parthasarathy, RT; Ponnuraja, C; Rahman, F; Ramachandran, R; Raman, B; Sakthivel, MR; Selvakumar, N; Shanmugam, G; Venkatesan, P | 1 |
| Jo, HJ; Kim, MS; Kim, N; Kim, SE; Lee, DH; Park, YS; Shin, CM | 1 |
| Brij, SO; Mamo, JP | 1 |
| Converse, PJ; Irwin, SM; Lenaerts, AJ; Li, SY; Mdluli, KE; Nuermberger, EL | 1 |
| Huh, HJ; Jeon, K; Jeong, BH; Koh, WJ; Lee, H; Lee, NY; Park, HY | 1 |
| Fukao, E; Honma, Y; Horiuchi, I; Nakahara, H; Oda, T; Uchigata, M | 1 |
| Almeida, D; Grosset, JH; Nuermberger, EL; Rosenthal, IM; Zhang, M | 1 |
| Bago, J; Bago, P; Bakula, V; Marusić, M; Pevec, B; Tomić, M | 1 |
| Arnaud, P; Berdot, S; Bouvet, E; Diamantis, S; Dombret, MC; Papy, E; Rioux, C; Ruimy, R | 1 |
| Huang, X; Li, Y; Shi, R; Yao, L; Zhang, G | 1 |
| Behillil, S; Berche, P; Coignard, H; Consigny, PH; Fraitag, S; Guet-Revillet, H; Jais, JP; Join-Lambert, O; Jullien, V; Le Guern, AS; Leflèche, A; Lortholary, O; Nassif, A; Nassif, X; Poirée, S; Ribadeau-Dumas, F; Thèze, J | 1 |
| Chung, HS; Han, SK; Kim, DK; Kim, JY; Kim, YW; Lee, CH; Lee, CT; Lee, J; Lee, JH; Lee, SM; Yang, SC; Yim, JJ; Yoo, CG; Yoon, HI | 1 |
| Burd, EM; Sharp, SE | 1 |
| Jacobs, F; Kubiak, J; Schaller, M; Stroelin, A | 1 |
| Bello, S; Torres, A | 1 |
| Burkhardt, O; Köhnlein, T; Pap, T; Welte, T | 1 |
| Gonzalez-Fernandez, F; Patel, NR; Reidy, JJ | 1 |
| Aimoni, C; Cassetta, MI; D'Errico, G; Esposito, S; Fallani, S; Mazzei, T; Motta, G; Novelli, A; Noviello, S; Passali, D; Pilucchi, S | 1 |
| De Benedetto, L; De Benedetto, M; Passali, D; Passali, GC; Salerni, L | 1 |
| Groeneveld, JH; Kuijper, EJ; van Nieuwkoop, C; Visser, LG | 1 |
| Davydow, DS; Reti, IM | 1 |
| Hoeffken, G; Meyer, HP; Verhoef, L; Winter, J | 1 |
6 review(s) available for moxifloxacin and Recrudescence
| Article | Year |
|---|---|
Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review.
Topics: Adult; Anti-Bacterial Agents; Antirheumatic Agents; Antiviral Agents; Betacoronavirus; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Testing; Drug Combinations; Female; Glucocorticoids; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lopinavir; Lung; Lupus Erythematosus, Systemic; Moxifloxacin; Mycophenolic Acid; Pandemics; Pneumonia, Viral; Prednisone; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; RNA, Viral; SARS-CoV-2; Tomography, X-Ray Computed | 2020 |
Moxifloxacin is an effective and safe candidate agent for tuberculosis treatment: a meta-analysis.
Topics: Antitubercular Agents; Drug Therapy, Combination; Fluoroquinolones; Humans; Moxifloxacin; Recurrence; Sputum; Treatment Outcome; Tuberculosis, Pulmonary | 2017 |
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.
Topics: Amikacin; Antitubercular Agents; Capreomycin; Carbapenems; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Fluoroquinolones; Humans; Kanamycin; Levofloxacin; Linezolid; Moxifloxacin; Recurrence; Treatment Failure; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2018 |
Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis.
Topics: Anti-Infective Agents; Aza Compounds; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Proton Pump Inhibitors; Quinolines; Randomized Controlled Trials as Topic; Recurrence; Retreatment | 2010 |
Nocardia keratitis after laser in situ keratomileusis: clinicopathologic correlation.
Topics: Administration, Topical; Anti-Bacterial Agents; Aza Compounds; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Imipenem; Keratitis; Keratomileusis, Laser In Situ; Keratoplasty, Penetrating; Middle Aged; Moxifloxacin; Necrosis; Nocardia asteroides; Nocardia Infections; Quinolines; Recurrence | 2005 |
[Rhinosinusitis: etiopathogenesis and antimicrobial therapy, an update].
Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Anti-Bacterial Agents; Aza Compounds; Bacteria; Child; Drug Resistance, Microbial; Endoscopy; Fluoroquinolones; Humans; Moxifloxacin; Mucociliary Clearance; Nasal Decongestants; Ofloxacin; Prevalence; Quinolines; Recurrence; Retrospective Studies; Risk; Sinusitis; Time Factors; Tomography, X-Ray Computed | 2006 |
5 trial(s) available for moxifloxacin and Recrudescence
| Article | Year |
|---|---|
Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients.
Topics: Adult; Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Middle Aged; Moxifloxacin; Quinolines; Recurrence; Sputum; Treatment Outcome; Tuberculosis, Pulmonary; Young Adult | 2013 |
Long-term follow up Helicobacter Pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aza Compounds; Breath Tests; Disease-Free Survival; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Kaplan-Meier Estimate; Longitudinal Studies; Male; Metronidazole; Middle Aged; Moxifloxacin; Organometallic Compounds; Peptic Ulcer; Quinolines; Recurrence; Stomach Neoplasms; Tetracycline; Treatment Outcome | 2013 |
Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial.
Topics: Adult; Anti-Infective Agents; Anti-Ulcer Agents; Aza Compounds; Breath Tests; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Moxifloxacin; Omeprazole; Organometallic Compounds; Proton Pump Inhibitors; Quinolines; Recurrence; Retreatment; Single-Blind Method; Tetracycline; Young Adult | 2009 |
Concentration of moxifloxacin in plasma and tonsillar tissue after multiple administration in adult patients.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Aza Compounds; Chronic Disease; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Palatine Tonsil; Plasma; Quinolines; Recurrence; Tonsillectomy; Tonsillitis | 2006 |
The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Clarithromycin; Community-Acquired Infections; Confidence Intervals; Double-Blind Method; Female; Fluoroquinolones; Humans; Liver Function Tests; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Pneumonia; Prospective Studies; Quinolines; Recurrence; Treatment Outcome | 2001 |
19 other study(ies) available for moxifloxacin and Recrudescence
| Article | Year |
|---|---|
Recurrent conjunctivitis secondary to Gram-positive bacillus, Bacillus thuringiensis.
Topics: Administration, Ophthalmic; Anti-Bacterial Agents; Bacillus thuringiensis; Conjunctivitis, Bacterial; Dexamethasone; Drug Therapy, Combination; Eye Infections, Bacterial; Glucocorticoids; Gram-Positive Bacterial Infections; Humans; Male; Middle Aged; Moxifloxacin; Ophthalmic Solutions; Recurrence; Tobramycin | 2018 |
Moxifloxacin Replacement in Contemporary Tuberculosis Drug Regimens Is Ineffective against Persistent Mycobacterium tuberculosis in the Cornell Mouse Model.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combination; Ethambutol; Female; Isoniazid; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Moxifloxacin; Mycobacterium tuberculosis; Recurrence; Tuberculosis, Pulmonary | 2018 |
Transformation Morphisms and Time-to-Extinction Analysis That Map Therapy Duration From Preclinical Models to Patients With Tuberculosis: Translating From Apples to Oranges.
Topics: Antitubercular Agents; Clinical Trials as Topic; Drug Discovery; Drug Evaluation, Preclinical; Ethambutol; Humans; Isoniazid; Models, Biological; Moxifloxacin; Mycobacterium tuberculosis; Recurrence; Sputum; Tuberculosis | 2018 |
Comparative roles of moxifloxacin and levofloxacin in the treatment of pulmonary multidrug-resistant tuberculosis: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Aza Compounds; China; Drug-Related Side Effects and Adverse Reactions; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Recurrence; Retrospective Studies; Sputum; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Young Adult | 2013 |
Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis.
Topics: Amikacin; Animals; Antitubercular Agents; Aza Compounds; DNA Gyrase; Drug Administration Schedule; Drug Resistance, Bacterial; Ethionamide; Female; Fluoroquinolones; Mice; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Recurrence; Rodent Diseases; Survival Analysis; Tuberculosis | 2013 |
Treating tuberculosis in the elderly population: a lesson in multi-disciplinary care.
Topics: Aged, 80 and over; Antitubercular Agents; Aza Compounds; Drug Interactions; England; Fluoroquinolones; Humans; Incidence; Latent Tuberculosis; Male; Moxifloxacin; Pharmacists; Quinolines; Radiography, Thoracic; Recurrence; Referral and Consultation; Treatment Outcome | 2013 |
Evaluation of moxifloxacin-containing regimens in pathologically distinct murine tuberculosis models.
Topics: Animals; Anti-Bacterial Agents; Antitubercular Agents; Colony Count, Microbial; Fluoroquinolones; Lung; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Moxifloxacin; Recurrence; Species Specificity; Treatment Outcome; Tuberculosis, Pulmonary | 2015 |
Treatment Outcomes with Fluoroquinolone-Containing Regimens for Isoniazid-Resistant Pulmonary Tuberculosis.
Topics: Adult; Aged; Antitubercular Agents; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Isoniazid; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Recurrence; Retrospective Studies; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2016 |
A case of meningococcal meningitis that was difficult to treat owing to concurrent ventriculitis.
Topics: Administration, Ophthalmic; Anti-Bacterial Agents; Ceftriaxone; Cerebral Ventriculitis; Drug Substitution; Fluoroquinolones; Humans; Magnetic Resonance Imaging; Male; Meningitis, Meningococcal; Middle Aged; Moxifloxacin; Recurrence; Treatment Outcome | 2016 |
Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Aza Compounds; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluoroquinolones; Isoniazid; Lung; Mice; Mice, Inbred BALB C; Moxifloxacin; Pyrazinamide; Quinolines; Recurrence; Rifampin; Time Factors; Treatment Outcome; Tuberculosis | 2008 |
[Use of moxifloxacin in tuberculosis regimen in a French teaching hospital].
Topics: Adult; Aged; Antitubercular Agents; Aza Compounds; Comorbidity; Drug Prescriptions; Drug Therapy, Combination; Drug Utilization; Female; Fluoroquinolones; France; HIV Infections; Hospitals, University; Humans; Male; Middle Aged; Moxifloxacin; Quinolines; Recurrence; Retrospective Studies; Tuberculosis; Young Adult | 2010 |
Efficacy of rifampin-moxifloxacin-metronidazole combination therapy in hidradenitis suppurativa.
Topics: Adult; Anti-Infective Agents; Antibiotics, Antitubercular; Aza Compounds; Drug Therapy, Combination; Female; Fluoroquinolones; Hidradenitis Suppurativa; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Metronidazole; Middle Aged; Moxifloxacin; Prognosis; Quinolines; Recurrence; Remission Induction; Retrospective Studies; Rifampin; Treatment Outcome; Young Adult | 2011 |
Retrospective comparison of levofloxacin and moxifloxacin on multidrug-resistant tuberculosis treatment outcomes.
Topics: Adult; Antitubercular Agents; Aza Compounds; Case-Control Studies; Chi-Square Distribution; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Female; Fluoroquinolones; Humans; Levofloxacin; Logistic Models; Male; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Odds Ratio; Ofloxacin; Quinolines; Recurrence; Remission Induction; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2011 |
Photo quiz: A 36-year-old with recurrent conjunctivitis.
Topics: Administration, Topical; Adult; Anti-Bacterial Agents; Aza Compounds; Bacterial Typing Techniques; Bacteriological Techniques; Ciprofloxacin; Conjunctivitis; Corneal Transplantation; Fluoroquinolones; Gram-Negative Bacterial Infections; Humans; Male; Microbial Sensitivity Tests; Microscopy; Moxifloxacin; Paracoccus; Quinolines; Recurrence; Surgical Wound Infection | 2012 |
Recurrent erysipelas secondary to a late prosthetic femoropopliteal bypass infection.
Topics: Aged; Anti-Infective Agents; Aza Compounds; Blood Vessel Prosthesis; Clindamycin; Coated Materials, Biocompatible; Erysipelas; Femoral Artery; Fluoroquinolones; Humans; Male; Moxifloxacin; Penicillin G; Peripheral Vascular Diseases; Popliteal Artery; Prosthesis-Related Infections; Quinolines; Recurrence; Reoperation | 2013 |
[Pneumococcus and quinolone resistance].
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Child, Preschool; Ciprofloxacin; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Genes, Bacterial; Humans; Male; Microbial Sensitivity Tests; Moxifloxacin; Multivariate Analysis; Mutation; Ofloxacin; Penicillin Resistance; Penicillins; Pneumococcal Infections; Pneumonia, Pneumococcal; Quinolines; Recurrence; Risk Factors; Streptococcus pneumoniae | 2003 |
Recurrent tendinitis after treatment with two different fluoroquinolones.
Topics: Achilles Tendon; Aged; Anti-Infective Agents; Asthma; Aza Compounds; Female; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines; Recurrence; Tendinopathy; Ultrasonography | 2004 |
Chronic bacterial prostatitis and relapsing Enterococcus faecalis bacteraemia successfully treated with moxifloxacin.
Topics: Anti-Infective Agents; Aza Compounds; Bacteremia; Chronic Disease; Enterococcus faecalis; Fluoroquinolones; Gram-Positive Bacterial Infections; Humans; Male; Middle Aged; Moxifloxacin; Prostatitis; Quinolines; Recurrence; Treatment Outcome | 2008 |
Electroconvulsive therapy and antibiotics: a case report.
Topics: Aged, 80 and over; Anti-Infective Agents; Aza Compounds; Cross Infection; Depressive Disorder, Major; Electroconvulsive Therapy; Electroencephalography; Female; Fluoroquinolones; Humans; Moxifloxacin; Quinolines; Recurrence; Respiratory Tract Infections; Retreatment | 2007 |